Full Year 2023 Investor Presentation
46
Investor presentation
Full year 2023
Semaglutide 2.0 mg s.c. brings patients needing treatment.
intensification to target
Phase 3 trial, SUSTAIN FORTE, completed and label application
approved in the US and the EU
Estimand
Trial product estimand
Treatment policy estimand
Once-weekly
semaglutide
2.0 mg
1.0 mg
2.0 mg
1.0 mg
HbA1c
2.2%*
1.9%
2.1%*
1.9%
reduction
Body weight
reduction
-6.9*
-6.0
-6.4
-5.6
(kg)
HbA1c <
7.0%1
68%
58%
1 ADA recommended treatment target
*Statistically significant
S.c.: subcutaneous; Sema: Semaglutide; T2D: Type 2 diabetes
Data from SUSTAIN FORTE
Semaglutide 2.0 mg showed superior HbA1c
reduction with more patients reaching target¹ versus
semaglutide 1.0 mg
Semaglutide 2.0 mg appeared to have a safe and
well-tolerated profile
Gastrointestinal adverse events were similar for
semaglutide 1.0 mg and 2.0 mg
3) Label expansion application approved in the US, JP
and the EU
Novo NordiskⓇView entire presentation